ANAVEX LIFE SCIENCES CORP.

Anavex Life Sciences announced plans to refresh its Board of Directors at the 2026 Annual Meeting, nominating two new independent directors, Mr. Gautam Patel and Dr. Adrian Senderowicz. The company is urging stockholders to reject an attempt by PVG Asset Management Corporation and Patrick S. Adams to replace the entire board. This follows the termination of former CEO Dr. Christopher Missling for cause and the appointment of Dr. Terrie Kellmeyer as interim CEO, as the company focuses on its blarcamesine pipeline and enhancing stockholder value.

Anavex Life Sciences Corp. announced the nomination of two new independent directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, as part of a refreshed Board slate for the 2026 Annual Meeting. The company also urged stockholders to reject an attempt by PVG Asset Management Corporation and Patrick S. Adams to gain control, citing PVG's insufficient proxy statement and small ownership stake. Anavex highlighted its focus on advancing its lead candidate, blarcamesine, and the appointment of Dr. Terrie Kellmeyer as interim CEO.

Anavex Life Sciences reported preliminary financial results for its second quarter ended March 31, 2026, showing a reduced net loss of $5.3 million and increased cash and cash equivalents to $127.4 million. The company also provided a business update, highlighting significant progress in its clinical programs for blarcamesine, including opening an IND for early Alzheimer's disease and aligning with the FDA on a Phase 3 protocol for Rett syndrome. These preliminary results and clinical advancements underscore a focused development strategy.

Anavex Life Sciences Corp. submitted a Compliance Plan to the Nasdaq Listing Qualifications Department on July 20, 2026. This plan addresses the company's non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the untimely filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The deficiency notification was received on May 20, 2026, but currently has no immediate effect on the company's stock listing. The Compliance Plan is under review by Nasdaq Staff, who may grant an extension if accepted.

Anavex Life Sciences Corp. announced that its Board of Directors has set September 24, 2026, as the date for the 2026 Annual Meeting of Stockholders. The record date for stockholders entitled to vote at the meeting will be July 31, 2026. Due to the meeting date being more than 30 days after the anniversary of the prior year's meeting, the company also provided revised deadlines for stockholder proposals and director nominations, setting July 10, 2026, as the deadline for submissions.

Anavex Life Sciences Corp. received a delinquency notification from Nasdaq on May 20, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. This puts the company in non-compliance with Nasdaq Listing Rule 5250(c)(1). The company has until July 20, 2026, to submit a plan to regain compliance, with a potential extension until November 16, 2026. The notice does not immediately affect the trading of its common stock.

Anavex Life Sciences Corp. announced it received a delinquency notification from Nasdaq on May 20, 2026. The notice states the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its failure to timely file its Form 10-Q for the quarterly period ended March 31, 2026. Anavex has until July 20, 2026, to submit a plan to regain compliance, and the company is actively working to complete the filing and submit the plan. This notification does not immediately affect the company's Nasdaq listing.

Anavex Life Sciences Corp. announced the departure of Felix Lauscher from his role as Chief Operating Officer on May 11, 2026. His departure is part of a broader reorganization of duties following the appointment of Dr. Terrie Kellmeyer as Interim Chief Executive Officer. During his tenure, Mr. Lauscher received a prorated annual base salary of $264,000 and was granted 50,000 stock options, of which 4,167 vested and remain exercisable. He was also offered two weeks' compensation in exchange for a general release.

Anavex Life Sciences Corp. announced the termination of Christopher Missling, PhD, as Chief Executive Officer for Cause, effective April 30, 2026, with a request for his resignation from the Board. The Board subsequently appointed Terrie Kellmeyer, PhD, as Interim Chief Executive Officer on May 4, 2026. Dr. Kellmeyer, with over 30 years of pharmaceutical experience, will receive an annual base salary of $500,000, a 30% annual bonus, a $150,000 signing bonus, and 200,000 stock options. The company also expects to file for an extension for its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Anavex Life Sciences Corp. announced the appointment of Terrie Kellmeyer, PhD, as Interim Chief Executive Officer. This follows the departure of former President and CEO Christopher Missling, PhD, on April 30, 2026, whose resignation was requested by the Board of Directors. Dr. Kellmeyer, previously Senior VP of Clinical Development and Senior Advisor, will lead the company's strategic initiatives to enhance clinical development programs. The company also expects to file a Form 12b-25 to extend the filing date for its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.